The translation of analgesic efficacy seen in preclinical pain models into the clinic is problematic and is associated with a number of factors that may result in the failure of clinical trials to detect the effect of investigational therapeutic agents. The use of translational pain biomarkers in phase I trials can potentially reduce some of these risks by measuring the interaction between the drug and its target (termed target engagement) in humans. To serve this purpose, sensory tests and other measures of pharmacological activity in nociceptive pathways need to be identified, based on the preclinical profile of the drug being tested and the feasibility of human assessments. Here we discuss some examples to assess the utility of sensory and related pain biomarkers in the early phase of evaluation of novel analgesics for confirmation of target engagement in humans. The emphasis is on the TRPV1 antagonists, but some other target mechanisms are also discussed in examining the validity of this approach.
INTRODUCTION
The transition between preclinical and clinical development phases is probably the highest hurdle for any drug, particularly for a novel analgesic. The large number of uncertainties, any of which could cause failure to translate preclinical efficacy into the clinic, includes differences in target pharmacology between preclinical species and humans, differences in the target role in mechanisms of animal and human pain states, differences in pharmacokinetics (PK), and the difficulty in predicting pharmacologically active concentrations in humans, as well as differences in adverse effects and toxicity.
Phase I clinical trials usually serve to address the issues of safety, tolerability, and PK in humans, and standard phase I studies are not usually designed to confirm therapeutic target engagement. Most commonly, efficacy is assessed by taking a safe and well-tolerated dose (sometimes the maximum tolerated dose) into a phase II proof-of-concept study in a target patient population. If those findings are positive, the compound then progresses to further development in large-scale phase IIb/III studies. More often than not, however, the outcome of proof-of-concept studies is negative; in such cases, many of the questions mentioned above remain unanswered, of which the most important question is whether or not the target has been invalidated so that no further work in this area is warranted.
The need to change this paradigm is illustrated by the average success rate for all therapeutic areas from 1992 to 2000 for 10 large pharmaceutical companies in the United States and Europe. 1 Only 11% of all compounds made it through clinical development during those years; the success rate was lower (8%) in central nervous system disorders, including chronic pain.
Sensory testing paradigms may serve as biomarkers of disease mechanisms, and thus help align preclinical and clinical development phases for new analgesics. These aspects have recently been reviewed in some detail by several authors. 2, 3 Here, we will discuss the use of sensory tests as efficacy biomarkers in early clinical development. We discuss the use of nociceptive pharmacodynamic (PD) markers in phase I-II and analyze several examples of their application in clinical trials, including the application of relevant experimental methods to eval-uate target engagement in the context of novel TRPV1 antagonists.
MECHANISM-BASED CLINICAL BIOMARKERS IN PHASE I CLINICAL TRIALS
Phase I clinical trials, although focused on human safety and PK endpoints, are opportunities for demonstrating PD effects in humans. This would potentially indicate whether there is receptor occupancy resulting in a functional effect, whether the effects are related to the pharmacokinetics of the compound (PK/PD relationships), and whether there is any separation of PD efficacy from the adverse effects and toxicological limits at the doses studied (therapeutic index).
For some targets, chemical biomarkers may be identified and used to estimate the level of target engagement. This is often done ex vivo, as when the blood of a drug-exposed human subject is treated with challenge agents to evoke a pharmacological response (e.g., release of prostanoids in whole blood as a measure of cyclooxygenase activity 4 ). Although seemingly simple and sufficiently robust (and potentially translatable between species), such markers do not test the target engagement of novel analgesics in the relevant tissue or pathway, and have not yet been validated. To achieve this, and specifically to potentially make accurate dose predictions, specific PD markers are needed that are sensitive to the target activity in nociceptive pathways or pain perception. We will review some of these sensory markers in the sections that follow.
CASE STUDIES WITH TRPV1 ANTAGONISTS
A large body of evidence has indicated a role for transient receptor potential vanilloid type 1 (TRPV1), a nonselective cation channel protein expressed predominantly by sensory neurons, in the detection of noxious painful stimuli such as capsaicin, acid, and heat. 5 The behaviors associated with pain evoked by thermal stimuli are attenuated in TRPV1 null (Ϫ/Ϫ) mice. 6 Pharmacological developments aimed at this target soon followed these findings. 7 These included the discovery of relevant compounds and the testing of the lead compounds in animal models, demonstrating their efficacy in inflammatory and neuropathic pain, as has been summarized in several recent reviews. 7, 8 TRPV1 antagonists seem particularly suitable for testing PD effects in phase I, because several types of challenge involving this target can be performed in healthy volunteers. TRPV1 is activated by capsaicin, noxious heat (Ͼ42°C) and protons (pH Ͻ 6), and can be sensitized to heat or protons by prostaglandins and several other proinflammatory agents. 9 -11 Thus, attenuation of heat pain, antagonism of capsaicin-evoked pain or flare, and alleviation of inflammatory hyperalgesia can all potentially serve as PD markers of TRPV1 antagonism in humans. To date, only a few such clinical studies have been reported, and only one has been published as a comprehensive article on the PD effects of a TRPV1 antagonist, SB-705498, in healthy humans. 12 This example will be used to examine the translation of the preclinical profile of TRPV1 antagonists into humans.
EVALUATION OF SB-705498, A NOVEL
TRPV1 ANTAGONIST
is a potent and selective multimodal TRPV1 antagonist. 13 Whole-cell patch-clamp electrophysiology showed that SB-705498 causes rapid and reversible inhibition of the capsaicin-mediated (IC 50 ϭ 3 nmol/L), acid-mediated (pH ϭ 5.3), or heat-mediated (50°C; IC 50 ϭ 6 nmol/L) activation of human TRPV1 (at Ϫ70 mV). 13 In vivo, the compound was shown to significantly attenuate inflammatory hyperalgesia evoked by intraplantar Freund's complete adjuvant in guinea pigs.
14 Therefore, the following experimental paradigms were considered to assess target engagement in phase I clinical trials and used to evaluate SB-705498 in human volunteers 12 : the capsaicin challenge, heat pain measurements, and assessment of inflammatory hyperalgesia induced by UV irradiation.
EXPERIMENTAL PAIN MODELS

Use of intradermal or topical capsaicin
Either of two formulations of capsaicin may be used in this model. Intradermal (ID) capsaicin formulation is prepared from purified capsaicin powder and dissolved in Tween-80 in water at a concentration of 10 mg/mL. Such injections cause pain, flare and hypersensitivity to heat (heat hyperalgesia at the site of injection), pin-prick and light touch (mechanical hyperalgesia and allodynia in the area extending beyond the injected site). [15] [16] [17] [18] Simone et al. 17 showed that injection of this vehicle alone does not cause secondary hyperalgesia; Sang et al. 18 showed that the spread of capsaicin cannot account for extension of hyperalgesia into adjacent nerve territories. Capsaicin cream (Axsain, 0.075% capsaicin w/w) may be applied to the skin on the volar aspect of one arm, left on the skin under occlusion for a period of time (e.g., 30 min) and then gently wiped off. This method of capsaicin administration also evokes pain, flare and hyperalgesia (as assessed in pilot experiments, data not shown). The topical formulation of capsaicin was used in the data presented below, primarily because of its ease of administration and relatively low intensity of evoked pain (vs ID injections) which was unlikely to interfere with other assessments.
UVB model
UV irradiation of the skin in humans is an established experimental method to evoke controlled skin inflammation and inflammatory hyperalgesia. 19 -21 To account for differences in individual sensitivity to UV, the minimum erythema dose for irradiation for each subject is established using a calibrated UV source (B spectrum, 290 -320 nm). This is done by irradiating several spots with increasing intensities of UVB light. Approximately 24 h later, threshold erythema is assessed either visually or using colorimetry. The dose of irradiation in the model is 3ϫ the minimum erythema dose, and subjects who do not develop threshold erythema at 1/3 of the maximum dose that can be safely administered to the subjects are excluded from the clinical trial.
Assessments of skin blood flow and heat pain threshold or tolerance are performed before and immediately after capsaicin application, and also before and 24 h after the UVB irradiation. Heat pain may be assessed on the side contralateral to the challenge, to serve as a control.
Heat pain threshold and tolerance assessments. A computer-controlled Peltier device (e.g., TSA-II; Medoc, Ramat Yishai, Israel) provides a robust way to measure thermal pain thresholds and tolerance. The probe may be positioned either on the volar aspect of the forearm (site of the capsaicin test) or on the upper thigh (site of the UVB test or the contralateral mirror-image site). The baseline (skin) temperature of the probe is usually held at 32°C. For threshold measurements, the temperature is gradually increased at a rate of 1°C/s (this rate is chosen to maximize the involvement of nociceptive fibers). 22 The subject is instructed to respond when the warmth detection and heat pain threshold (first sensation of warmth and heat pain, respectively) or heat pain tolerance (the maximum tolerable pain) are reached. The cutoff temperature for all thermal tests is set to 50°C, to prevent skin injury. Both the capsaicin test and UVB irradiation have been shown to induce pronounced thermal hyperalgesia, as evidenced by substantially lower heat pain or tolerance thresholds (or both) in the sensitized versus normal skin (see Figure 2 in Chizh et al. 12 ). Flare intensity and area. Peripheral nociceptor activation may be assessed by monitoring cutaneous blood flow using imaging techniques such as infrared thermography and laser Doppler imaging (e.g., LDI-2; Moor Instruments, Axminster, Devon, UK). Activation of nociceptive fibers in the skin by capsaicin has been shown to release vasoactive neuropeptides that cause dilatation of small blood vessels in the skin (flare 23 ). In the case of UVB irradiation, flare is most likely caused by release of prostaglandins 24 ; a neurogenic contribution to UVBevoked flare is also possible. 25 An area extending well beyond the challenge site (i.e., either capsaicin or UVB irradiation) is scanned and the flare area is calculated from all pixels around the stimulation site in which flux values exceeded the 95th percentile of the baseline distribution. The mean blood flow in the area of flare is also calculated using relative flux (arbitrary units). Both the capsaicin challenge test and UVB irradiation induced flare. 12 In the case of capsaicin, the flare was apparently of axon-reflex type, because the area of flare extended well beyond the area of capsaicin application (see Figure  3 in Chizh et al. 12 ). With UVB irradiation, the area of flare was largely confined to the site of irradiation.
Sample size considerations.
Calculations of the sample size necessary for detection of meaningful changes in test endpoints rely on prior knowledge, which in the case of a novel mechanism may be absent. Indeed, no data had been available for sample size calculations based on effects of TRPV1 antagonists on capsaicinevoked flare. Nonetheless, in the case of heat pain threshold on nonsensitized skin and UVB-induced thermal hyperalgesia, one may use as a benchmark previous data with established analgesics already in clinical use (i.e., opioids and cyclooxygenase inhibitors, respectively). Based on the results from published studies using the UVB model, estimates of between-subject variability for heat pain assessments are between 1.6°C and 2.6°C and estimates of within-subject variability are between 0.69°C and 1.11°C. Based on these estimates of variability and a sample size of 20 subjects (feasibility-based), it was estimated that the lower and upper bounds of the 95% confidence interval, for the comparison, SB-705498 versus placebo, would be within 0.7°C and 0.9°C of the point estimate.
USE OF BIOMARKERS IN SB-705498 EARLY DEVELOPMENT PROGRAM: DID THE PRECLINICAL PHARMACOLOGICAL PROFILE TRANSLATE INTO HUMANS?
Capsaicin-evoked flare and sensitization
In the first human study of the TRPV1 antagonist SB-705498, flare evoked by topical dermal administration of capsaicin cream was significantly reduced by SB-705498 versus placebo. 12 This is consistent with in vitro data on the ability of this compound to competitively antagonize capsaicin-evoked activation of HEK293 cells expressing the human TRPV1. 13 The area of flare after SB-7054998 administration was inversely correlated with the plasma levels of the compound, a finding that both confirms that the reduction of flare was due to the active treatment and suggests that the maximum PD efficacy was not achieved.
Notably, the heat hyperalgesia induced by capsaicin was not attenuated by the administration of SB-705498 versus placebo. 12 This may be explained by a greater level of TRPV1 receptor activation by the combined application of heat and capsaicin and by the voltagedependent nature of the SB-705498 antagonism, 13 which would require higher concentrations of the antagonist to produce detectable effects.
Noxious heat perception
SB-705498 significantly elevated heat pain thresholds in normal skin when measured at different locations (forearm, thigh), compared with placebo. This effect is consistent with the in vitro data on the blockade by SB-705498 of heat-evoked activation of the TRPV1 receptor. 13 Unfortunately, no in vivo data on the effect of SB-705498 in preclinical species are available; however, one of the studies of TRPV1 knockout mice demonstrated the receptor involvement in physiological thermonociception. 26, 27 There are also animal data with other TRPV1 selective antagonists demonstrating elevation of the withdrawal reflex threshold in response to noxious heat. 28 Thus, the alleviation by SB-705498 of heat-evoked pain is in line with the preclinical data and confirms the role of TRPV1 as a heat sensor in humans.
UVB-induced inflammatory hyperalgesia
SB-705498 significantly increased heat pain threshold and tolerance (vs placebo) in healthy subjects at the sites that were inflamed after UVB irradiation. 12 Both heat pain threshold and tolerance were substantially higher in normal skin versus inflamed, a result that implies attenuation of inflammatory hyperalgesia in humans. Again, there was a correlation between this effect and plasma concentration of SB-705498. Because inflammation is known to involve tissue acidification and release of endogenous proinflammatory agents, these results are consistent with the in vitro properties of the TRPV1 receptor, such as its sensitivity to protons (pH Ͻ 6) and sensitization by prostaglandins. 29 -31 The in vivo evidence supporting the role of TRPV1 in inflammatory pain comes from studies of TRPV1 knockout mice. 26, 27 As already discussed here, several TRPV1 antagonists have demonstrated reversal of inflammatory hyperalgesia in animal models of inflammatory pain, including SB-705498.
14 Thus, the effects of SB-705498 in humans confirm the importance of this target in inflammatory pain suggested by the preclinical data.
OTHER TRPV1 ANTAGONISTS
Although some limited information on PD effects of other TRPV1 antagonists in humans has recently become available, none of the reports mention effects on capsaicin-evoked flare or experimental inflammation. Thus, solid conclusions on the effects of TRPV1 antagonists on those endpoints will require confirmation of the findings on SB-705498 by clinical studies of other compounds of this class. What has been confirmed by brief preliminary reports on other TRPV1 antagonists available so far is the effects on heat pain, and these appear to be consistent with the findings for SB-705498. Thus, AstraZeneca's AZD1386 was investigated in two phase I studies in healthy volunteers and found to increase mean thresholds for warmth detection and heat pain; the effect on heat pain was significant versus placebo (citeline.com, TrialTrove ID-080799 and ID-095917). Importantly, the PD effects of AZD1386 on heat pain persisted after repeated dosing of the compound. Merck-Neurogen have also reported translational PD effects of their TRPV1 antagonist MK-2295 on thermonociception (presentation at Keystone meeting on Neurobiology of Pain and Analgesia, 2009; http://www.keystonesymposia.org). The compound reduced sensitivity to noxious heat in animals (hotplate in rodents and tail immersion in rhesus monkeys) and in healthy human subjects (quantitative thermal sensory tests, pain evoked by hand immersion into or sipping hot water); details of the tests or magnitude of the effects have not yet been reported.
OTHER EXAMPLES: PHASE I TRANSLATIONAL MARKERS OF SODIUM CHANNEL BLOCKADE AND CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISM
Imaging techniques such as infrared thermography and laser Doppler imaging (LDI) can detect minute changes in blood flow (for example, in the skin), related to the release of endogenous vasoactive substances. Because many nociceptive fibers contain vasoactive neuropeptides (e.g., calcitonin gene-related peptide, CGRP), their activation causes axon reflex-mediated vasodilation. [32] [33] [34] [35] Thus, pharmacological agents capable of reducing nociceptor excitability are expected to reduce such axon-reflex vasodilatation. Noxious stimulation of the skin in humans (e.g., using capsaicin or intradermal electrical stimulation) evokes skin flare, which may be attenuated by local or systemic administration of sodium channel blockers and opioids. 36 -38 Importantly, in the case of systemic administration of the sodium channel blocker lidocaine, the effects on flare and on secondary hyperalgesia are observed at clinically efficacious doses of the drug. 14,36 -39 This implies that measures of neurogenic flare and hyperalgesia may serve as predictive PD markers for these and potentially other targets.
One more recent example of using neurogenic skin flare as a translational PD marker is Merck's CGRP antagonist, MK-0974. Given the established role of CGRP in neurogenic inflammation, capsaicin-evoked flare may be used as a marker of CGRP activation in both preclinical species and humans. The compound showed an attenuation of the capsaicin-evoked flare endpoints both in monkeys 40 and in healthy volunteers in phase I study. 41 The efficacious doses of MK-0974 tested in healthy volunteers were then taken into a clinical study of acute migraine, a condition known to involve neurogenic inflammation of the dura due to a vicious circle of excitation in the trigeminal nociceptive system. 42 The compound was shown to significantly alleviate headache in migraineurs, with efficacy comparable to that of some triptans, 42 thus confirming the usefulness of translational PD markers for identifying active doses of the CGRP antagonist.
Conclusions
The use of clinical biomarkers in phase I trials can potentially accelerate the development, or appropriate abandonment, of an analgesic program. The choice of sensory tests and the testing paradigm to show target engagement depends on the preclinical profile of the drug being tested. Nevertheless, PD responses to analgesic therapy may still vary between animal pain models and patients, based in part on species differences and genetic variability within species, differences in PK, differences in pain mechanisms between animal and human models, and differences in environmental influences. These reasons for failure must be distinguished from failure to modulate the target.
The examples discussed in this review confirm the usefulness of clinical biomarkers in the early phase evaluation of novel analgesics for confirmation of target engagement in humans. The ability to assess dose-response and exposure-response relationships has the potential to facilitate the design of dose-finding clinical trials in appropriate pain patients. In some cases, clinical efficacy data exist to support the validity of the dose-selection on the basis of human PD activity. More clinical efficacy data on analgesics with different mechanisms are needed to further confirm the reliability of this approach.
